4-phenylbutylamine has been researched along with Carcinoma, Ductal, Pancreatic in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cao, P; Chang, A; Feng, Y; Guo, W; Hao, J; Li, H; Li, S; Liu, W; She, C; Wang, X; Wu, C; Xie, Y; Xu, C; Yang, Y | 1 |
1 other study(ies) available for 4-phenylbutylamine and Carcinoma, Ductal, Pancreatic
| Article | Year |
|---|---|
Combination of RUNX1 inhibitor and gemcitabine mitigates chemo-resistance in pancreatic ductal adenocarcinoma by modulating BiP/PERK/eIF2α-axis-mediated endoplasmic reticulum stress.
Topics: Animals; Carcinoma, Pancreatic Ductal; Core Binding Factor Alpha 2 Subunit; Gemcitabine; Humans; Mice; Pancreatic Neoplasms; Peptide Initiation Factors | 2023 |